An extra X chromosome occurs in ~ 1 in 1000 females, resulting in a karyotype 47,XXX also known as trisomy X syndrome (TXS). Women with TXS appear to be at increased risk for premature ovarian insufficiency; however, very little research on this relationship has been conducted. The objective of this case-control study is to compare ovarian function, as measured by anti-mullerian hormone (AMH) levels, between girls with TXS and controls. Serum AMH concentrations were compared between 15 females with TXS (median age 13.4 years) and 26 controls (median age 15.1 years). Females with TXS had significantly lower serum AMH compared to controls (0.7 ng/mL (IQR 0.2–1.7) vs 2.7 (IQR 1.3–4.8), p < 0.001). Additionally, girls with TXS were much more likely to have an AMH below the 2.5th percentile for age with 67% of them meeting these criteria (OR 11, 95% CI 2.3–42). Lower AMH concentrations in females with TXS may represent an increased risk for primary ovarian insufficiency in these patients and potentially a narrow window of opportunity to pursue fertility preservation options. Additional research is needed to understand the natural history of low AMH concentrations and future risk of premature ovarian insufficiency in girls with TXS.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Jacobs P, Baikie A, Brown W, Macgregor T, Maclean N, Harnden D. Evidence for the existence of the human "superfemale". Lancet. 1959;274:423–5.
Jacobs P. The incidence and etiology of sex chromosome abnormalities in man. Birth Defects Orig Artic Ser. 1979;15:3–14.
Nielsen J, Wohlert M. Sex chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Birth Defects Orig Artic Ser. 1990;26(4):209–23.
Berglund A, Viuff MH, Skakkebaek A, Chang S, Stochholm K, Gravholt CH. Changes in the cohort composition of turner syndrome and severe non-diagnosis of Klinefelter, 47,XXX and 47,XYY syndrome: a nationwide cohort study. Orphanet J Rare Dis. 2019;14(1):16. https://doi.org/10.1186/s13023-018-0976-2.
Tartaglia NR, Howell S, Sutherland A, Wilson R, Wilson L. A review of trisomy X (47,XXX). Orphanet J Rare Dis. 2010;5:8.
Tartaglia N. Medical problems and follow-up in trisomy X syndrome. KS&A Scientific Advisory Committee Conference; Los Angeles. 2009.
Tartaglia NR, Ayari N, Hutaff-Lee C, Boada R. Attention-deficit hyperactivity disorder symptoms in children and adolescents with sex chromosome aneuploidy: XXY, XXX, XYY, and XXYY. J Dev Behav Pediatr. 2012;33(4):309–18.
Linden MG, Bender BG. Fifty-one prenatally diagnosed children and adolescents with sex chromosome abnormalities. Am J Med Genet. 2002;110(1):11–8. https://doi.org/10.1002/ajmg.10394.
Otter M, Schrander-Stumpel CT, Didden R, Curfs LM. The psychiatric phenotype in triple X syndrome: new hypotheses illustrated in two cases. Dev Neurorehabil. 2012;15(3):233–8. https://doi.org/10.3109/17518423.2012.655799.
Sugawara N, Maeda M, Manome T, Nagai R, Araki Y. Patients with 47, XXX karyotype who experienced premature ovarian failure (POF): two case reports. Reprod Med Biol. 2013;12(4):193–5. https://doi.org/10.1007/s12522-013-0158-9.
Skalba P, Cygal A, Gierzynska Z. A case of premature ovarian failure (POF) in a 31-year-old woman with a 47,XXX karyotype. Endokrynol Pol. 2010;61(2):217–9.
Itu M, Neelam T, Ammini AC, Kucheria K. Primary amenorrhoea in a triple X female. Aust N Z J Obstet Gynaecol. 1990;30(4):386–8. https://doi.org/10.1111/j.1479-828x.1990.tb02039.x.
Menon V, Edwards RL, Butt WR, Bluck M, Lynch SS. Review of 59 patients with hypergonadotrophic amenorrhoea. Br J Obstet Gynaecol. 1984;91(1):63–6. https://doi.org/10.1111/j.1471-0528.1984.tb05280.x.
Smith HC, Seale JP, Posen S. Premature ovarian failure in a triple X female. J Obstet Gynaecol Br Commonw. 1974;81(5):405–9. https://doi.org/10.1111/j.1471-0528.1974.tb00488.x.
Holland CM. 47,XXX in an adolescent with premature ovarian failure and autoimmune disease. J Pediatr Adolesc Gynecol. 2001;14(2):77–80. https://doi.org/10.1016/s1083-3188(01)00075-4.
Michalak DP, Zacur HA, Rock JA, Woodruff JD. Autoimmunity in a patient with 47,XXX karyotype. Obstet Gynecol. 1983;62(5):667–9.
Goswami R, Goswami D, Kabra M, Gupta N, Dubey S, Dadhwal V. Prevalence of the triple X syndrome in phenotypically normal women with premature ovarian failure and its association with autoimmune thyroid disorders. Fertil Steril. 2003;80(4):1052–4. https://doi.org/10.1016/s0015-0282(03)01121-x.
Tungphaisal S, Jinorose U. True 47,XXX in a patient with premature ovarian failure: the first reported case in Thailand. J Med Assoc Thail. 1992;75(11):661–5.
Villanueva AL, Rebar RW. Triple-X syndrome and premature ovarian failure. Obstet Gynecol. 1983;62(3 Suppl):70s–3s.
Kodandapani S, Pai MV, Nambiar J, Moka R. Premature ovarian aging in primary infertility: triple X syndrome. J Hum Reprod Sci. 2011;4(3):153–4. https://doi.org/10.4103/0974-1208.92292.
Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8(6):331–41. https://doi.org/10.1038/nrendo.2011.224.
Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606–14. https://doi.org/10.1056/NEJMcp0808697.
Ratcliffe S, Butler G, Jones M. Edinburgh study of growth and development of children with sex chromosome abnormalities. Birth Defects Orig Artic Ser. 1990;26(4):1–44.
Stagi S, di Tommaso M, Scalini P, Lapi E, Losi S, Bencini E, et al. Triple X syndrome and puberty: focus on the hypothalamus-hypophysis-gonad axis. Fertil Steril. 2016;105(6):1547–53. https://doi.org/10.1016/j.fertnstert.2016.02.019.
Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170–5. https://doi.org/10.1016/j.fertnstert.2010.04.006.
Hagen CP, Aksglaede L, Sorensen K, Main KM, Boas M, Cleemann L, et al. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):5003–10. https://doi.org/10.1210/jc.2010-0930.
Hamza RT, Mira MF, Hamed AI, Ezzat T, Sallam MT. Anti-mullerian hormone levels in patients with turner syndrome: relation to karyotype, spontaneous puberty, and replacement therapy. Am J Med Genet A. 2018;176(9):1929–34. https://doi.org/10.1002/ajmg.a.40473.
Lunding SA, Aksglaede L, Anderson RA, Main KM, Juul A, Hagen CP, et al. AMH as predictor of premature ovarian insufficiency: a longitudinal study of 120 turner syndrome patients. J Clin Endocrinol Metab. 2015;100(7):E1030–8. https://doi.org/10.1210/jc.2015-1621.
Tartaglia N, Howell S, Wilson R, Janusz J, Boada R, Martin S, et al. The eXtraordinarY kids clinic: an interdisciplinary model of care for children and adolescents with sex chromosome aneuploidy. J Multidiscip Healthc. 2015;8:323–34.
Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88(12):5957–62. https://doi.org/10.1210/jc.2003-030727.
Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011;96(8):2532–9. https://doi.org/10.1210/jc.2010-2776.
Castillo S, Lopez F, Tobella L, Salazar S, Daher V. The cytogenetics of premature ovarian failure. Rev Chil Obstet Ginecol. 1992;57(5):341–5.
Otter M, Schrander-Stumpel CT, Curfs LM. Triple X syndrome: a review of the literature. Eur J Hum Genet. 2009.
Collen RJ, Falk RE, Lippe BM, Kaplan SA. A 48,XXXX female with absence of ovaries. Am J Med Genet. 1980;6(4):275–8. https://doi.org/10.1002/ajmg.1320060404.
Prueitt RL, Ross JL, Zinn AR. Physical mapping of nine Xq translocation breakpoints and identification of XPNPEP2 as a premature ovarian failure candidate gene. Cytogenet Cell Genet. 2000;89(1–2):44–50. https://doi.org/10.1159/000015560.
Bione S, Rizzolio F, Sala C, Ricotti R, Goegan M, Manzini MC, et al. Mutation analysis of two candidate genes for premature ovarian failure, DACH2 and POF1B. Hum Reprod. 2004;19(12):2759–66. https://doi.org/10.1093/humrep/deh502.
Quilter CR, Karcanias AC, Bagga MR, Duncan S, Murray A, Conway GS, et al. Analysis of X chromosome genomic DNA sequence copy number variation associated with premature ovarian failure (POF). Hum Reprod. 2010;25(8):2139–50. https://doi.org/10.1093/humrep/deq158.
Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2009;106(27):11294–9. https://doi.org/10.1073/pnas.0903854106.
Erhart LM, Lankat-Buttgereit B, Schmidt H, Wenzel U, Daniel H, Goke R. Flavone initiates a hierarchical activation of the caspase-cascade in colon cancer cells. Apoptosis. 2005;10(3):611–7. https://doi.org/10.1007/s10495-005-1895-y.
Johnson EK, Finlayson C, Rowell EE, Gosiengfiao Y, Pavone ME, Lockart B, et al. Fertility preservation for pediatric patients: current state and future possibilities. J Urol. 2017;198(1):186–94. https://doi.org/10.1016/j.juro.2016.09.159.
Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014;124(1):193–7. https://doi.org/10.1097/01.AOG.0000451757.51964.98.
Nahata L, Quinn GP, Tishelman AC, Section OE. Counseling in pediatric populations at risk for infertility and/or sexual function concerns. Pediatrics. 2018;142(2). https://doi.org/10.1542/peds.2018-1435.
Dennis A, Howell S, Cordeiro L, Tartaglia N. “How should I tell my child?” disclosing the diagnosis of sex chromosome aneuploidies. J Genet Couns. 2015;24(1):88–103. https://doi.org/10.1007/s10897-014-9741-4.
Lefebvre T, Dumont A, Pigny P, Dewailly D. Effect of obesity and its related metabolic factors on serum anti-mullerian hormone concentrations in women with and without polycystic ovaries. Reprod BioMed Online. 2017;35(3):325–30. https://doi.org/10.1016/j.rbmo.2017.05.013.
Simoes-Pereira J, Nunes J, Aguiar A, Sousa S, Rodrigues C, Sampaio Matias J, et al. Influence of body mass index in anti-mullerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit. Endocrine. 2018;61(1):144–8. https://doi.org/10.1007/s12020-018-1555-y.
Dong YZ, Zhou FJ, Sun YP. Psychological stress is related to a decrease of serum anti-mullerian hormone level in infertile women. Reprod Biol Endocrinol. 2017;15(1):51. https://doi.org/10.1186/s12958-017-0271-4.
Henes M, Froeschlin J, Taran FA, Brucker S, Rall KK, Xenitidis T, et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behcet's disease and spondyloarthritis on anti-mullerian hormone levels. Rheumatology (Oxford). 2015;54(9):1709–12. https://doi.org/10.1093/rheumatology/kev124.
Szydlowska I, Marciniak A, Brodowska A, Lisak M, Przysiecka S, Rozanski J. Assessment of ovarian reserve as an indicator of fertility and health consequences in patients with chronic kidney disease stages 3-4. Gynecol Endocrinol. 2018;34(11):944–8. https://doi.org/10.1080/09513590.2018.1473364.
The authors wish to thank the study participants in the eXtraordinarY Kids Clinic and their families. We also acknowledge Esoterix Laboratories, in particular Walt Chandler, PhD, Kelly Chun, PhD, and Steve Phagoo, PhD. Additionally, we acknowledge funding from the National Center for Advancing Translational Sciences (NIH/NCATS) Colorado CTSA (UL1TR002535), the National Institute of Child Health and Human Development (NIH/NICHD) (K23HD092588), the American Heart Association (13CRP14120015), the National Institute of Digestion, Diabetes, and Kidney Disease (NIH/NIDDK) (K23DK107871), the University of Colorado Departments of Obstetrics and Gynecology and Pediatrics.
This work was financially supported by the following: National Institute of Child Health and Human Development (NIH/NICHD) (K23HD092588), National Institute of Digestion, Diabetes, and Kidney Disease (NIH/NIDDK) (K23DK107871), National Center for Advancing Translational Sciences (NIH/NCATS) Colorado CTSA (UL1TR002535), American Heart Association (13CRP14120015), University of Colorado Department of Obstetrics and Gynecology Research Funds, and University of Colorado Department of Pediatrics. Availability of Data and Material
All data generated or analyzed during this study are included in this published article.
Conflict of Interest
NT and SD serve as medical advisors and SH on the board of directors for the advocacy group AXYS (Association for X&Y syndromes).
Consent to Participate
The local institutional review board (COMIRB #08-0512 and #10-1288) approved these protocols and all parents provided written informed consent and girls provided assent as age appropriate. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
Contents are the authors’ sole responsibility and do not necessarily represent official NIH or AHA views.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Davis, S.M., Soares, K., Howell, S. et al. Diminished Ovarian Reserve in Girls and Adolescents with Trisomy X Syndrome. Reprod. Sci. (2020). https://doi.org/10.1007/s43032-020-00216-4
- Trisomy X syndrome (TXS)
- Primary ovarian insufficiency (POI)
- Anti-mullerian hormone (AMH)
- Sex chromosome aneuploidy